Search CTL/CD8+ T-Cell Epitope Database

Found 3 matching records:

Displaying record number 59401

HXB2 Location	Pol(942-950) Integrase(227-235) DNA(4908..4934)	Pol Epitope Map
Author Location	Pol
Epitope	YRDSRDPLW	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*38)
Immunogen	HIV-1 infection
Patient MHC/HLA	LTNP/EC-17: A*11, A*24, B*35, B*38, Cw*04, Cw*12
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, immunodominance, novel epitope

Notes

• The study compared B*27/*57-positive versus negative patients among a cohort of long-term nonprogressors and elite controllers with B*27/B*57-negative progressors. Overlapping 15-mers that elicited responses in multiple patients, or were among the strongest responses in a single patient, were narrowed down by truncation to define optimal epitopes, 11 of which were novel.
• YRDSRDPLW was recognized by 1/1 LTNP/EC, and 1/1 had it as a dominant response. The restricting HLA (B*38) was confirmed experimentally.

References

Migueles2015 Stephen A. Migueles, Daniel Mendoza, Matthew G. Zimmerman, Kelly M. Martins, Sushila A. Toulmin, Elizabeth P. Kelly, Bennett A. Peterson, Sarah A. Johnson, Eric Galson, Kate O. Poropatich, Andy Patamawenu, Hiromi Imamichi, Alexander Ober, Catherine A. Rehm, Sara Jones, Claire W. Hallahan, Dean A. Follmann, and Mark Connors. CD8+ T-Cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types. EBioMedicine, 2(1):46-58, Jan 2015. PubMed ID: 26137533. Show all entries for this paper.

Displaying record number 61740

HXB2 Location	Pol(942-950) Integrase(227-235) DNA(4908..4934)	Pol Epitope Map
Author Location	Pol(227-235)
Epitope	YRDSRDPLW	Epitope Alignment
Epitope Name	YW9
Species (MHC/HLA)	human(B*38)
Immunogen
Experimental methods
Keywords	optimal epitope

Notes

• C. Brander notes this as a B*38-restricted Pol epitope (Migueles2015).

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 61027

HXB2 Location	Pol(942-950) Integrase(227-235) DNA(4908..4934)	Pol Epitope Map
Author Location	Integrase(227-235)
Epitope	YRDSRDPLW	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B*3801)
Immunogen	HIV-1 infection
Patient MHC/HLA	11439: A*0101, A*2902, B*3801, B*4403, Cw*1203, Cw*1601; 25327: A*2301, A*2601, B*3801, B*3801, Cw*0401, Cw*1203
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	acute/early infection

Notes

• The extent to which set-point viremia is affected by early HIV-infection T cell responses to either conserved or variable epitopes was studied. 23 ART-naive subjects were characterized for CTL responses for 6 months, postinfection. While most CTL responses (73/123) were targeted against variable HIV-1 epitopes, recognition of conserved epitopes (16/123) was associated with lower set point viremia. This was independent of HLA type and also functional avidity of the CTL response. Most of the conserved responses were targeted to Gag and Pol epitopes.
• YRDSRDPLW, restricted by B*3801, was recognized by 2 patients with the restricting allele.

References

Kunwar2013 Pratima Kunwar, Natalie Hawkins, Warren L. Dinges, Yi Liu, Erin E. Gabriel, David A. Swan, Claire E. Stevens, Janine Maenza, Ann C. Collier, James I. Mullins, Tomer Hertz, Xuesong Yu, and Helen Horton. Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design. PLoS One, 8(5):e64405, 2013. PubMed ID: 23741326. Show all entries for this paper.